Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications
Background: Monoclonal antibodies (mAbs) represent the most numerous and significant group of biotherapeutics. While mAbs have undoubtedly improved treatment for many chronic diseases, including inflammatory diseases, they are typically expensive for health care systems and patients. Consequently, a...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-07-01
|
Series: | Medicine Access @ Point of Care |
Online Access: | https://doi.org/10.1177/23992026211027692 |
id |
doaj-dd47d22b353f4e3388269f12815b0b9c |
---|---|
record_format |
Article |
spelling |
doaj-dd47d22b353f4e3388269f12815b0b9c2021-07-09T21:33:19ZengSAGE PublishingMedicine Access @ Point of Care2399-20262021-07-01510.1177/23992026211027692Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implicationsBiljana Tubic0Vanda Marković-Peković1Saša Jungić2Eleonora Allocati3Brian Godman4Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and HerzegovinaDepartment of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and HerzegovinaUniversity Clinical Centre of Republic of Srpska, Banja Luka, Bosnia and HerzegovinaIstituto di Ricerche Farmacologiche ‘Mario Negri’ IRCCS, Milan, ItalySchool of Pharmaceutical Sciences, University Sains Malaysia, Penang, MalaysiaBackground: Monoclonal antibodies (mAbs) represent the most numerous and significant group of biotherapeutics. While mAbs have undoubtedly improved treatment for many chronic diseases, including inflammatory diseases, they are typically expensive for health care systems and patients. Consequently, access to mAbs has been a problem for many patients especially among Central and Eastern European (CEE) countries. However, biosimilars can potentially help with costs, although there are concerns with their effectiveness and safety. This includes biosimilars for long-acting insulin analogues. Aim: Assess the availability and use of biological medicines, including biosimilars within Bosnia and Herzegovina (B&H). Methods: Assess the availability of mAbs via the current lists of approved and accessed mAbs versus those licenced in Europe and the United States and their utilisation, as well as specifically insulin glargine and its biosimilars, within B&H. Results: The availability of the mAbs in B&H appears satisfactory, which is encouraging. However, current usage is limited to a few mAbs which is a concern for subsequent patient care especially with limited use of biosimilars to address issues of affordability. We also see limited use of biosimilar insulin glargine. Conclusion The limited use of mAbs including biosimilars needs to be addressed in B&H to improve the future care of patients within finite resources. We will monitor these developments.https://doi.org/10.1177/23992026211027692 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Biljana Tubic Vanda Marković-Peković Saša Jungić Eleonora Allocati Brian Godman |
spellingShingle |
Biljana Tubic Vanda Marković-Peković Saša Jungić Eleonora Allocati Brian Godman Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications Medicine Access @ Point of Care |
author_facet |
Biljana Tubic Vanda Marković-Peković Saša Jungić Eleonora Allocati Brian Godman |
author_sort |
Biljana Tubic |
title |
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications |
title_short |
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications |
title_full |
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications |
title_fullStr |
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications |
title_full_unstemmed |
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications |
title_sort |
availability and accessibility of monoclonal antibodies in bosnia and herzegovina: findings and implications |
publisher |
SAGE Publishing |
series |
Medicine Access @ Point of Care |
issn |
2399-2026 |
publishDate |
2021-07-01 |
description |
Background: Monoclonal antibodies (mAbs) represent the most numerous and significant group of biotherapeutics. While mAbs have undoubtedly improved treatment for many chronic diseases, including inflammatory diseases, they are typically expensive for health care systems and patients. Consequently, access to mAbs has been a problem for many patients especially among Central and Eastern European (CEE) countries. However, biosimilars can potentially help with costs, although there are concerns with their effectiveness and safety. This includes biosimilars for long-acting insulin analogues. Aim: Assess the availability and use of biological medicines, including biosimilars within Bosnia and Herzegovina (B&H). Methods: Assess the availability of mAbs via the current lists of approved and accessed mAbs versus those licenced in Europe and the United States and their utilisation, as well as specifically insulin glargine and its biosimilars, within B&H. Results: The availability of the mAbs in B&H appears satisfactory, which is encouraging. However, current usage is limited to a few mAbs which is a concern for subsequent patient care especially with limited use of biosimilars to address issues of affordability. We also see limited use of biosimilar insulin glargine. Conclusion The limited use of mAbs including biosimilars needs to be addressed in B&H to improve the future care of patients within finite resources. We will monitor these developments. |
url |
https://doi.org/10.1177/23992026211027692 |
work_keys_str_mv |
AT biljanatubic availabilityandaccessibilityofmonoclonalantibodiesinbosniaandherzegovinafindingsandimplications AT vandamarkovicpekovic availabilityandaccessibilityofmonoclonalantibodiesinbosniaandherzegovinafindingsandimplications AT sasajungic availabilityandaccessibilityofmonoclonalantibodiesinbosniaandherzegovinafindingsandimplications AT eleonoraallocati availabilityandaccessibilityofmonoclonalantibodiesinbosniaandherzegovinafindingsandimplications AT briangodman availabilityandaccessibilityofmonoclonalantibodiesinbosniaandherzegovinafindingsandimplications |
_version_ |
1721310092768313344 |